News

Elevance Health price target raised to $510 from $480 at Truist
Truist raised the firm’s price target on Elevance Health (ELV) to $510 from $480 and keeps a Buy rating on the shares as part of a broader ...
Barclays Sticks to Its Buy Rating for Elevance Health (ELV)
Barclays analyst Andrew Mok CFA maintained a Buy rating on Elevance Health (ELV – Research Report) today and set a price target of $512.00. The ...